This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF2 / Rho guanine nucleotide exchange factor 2 · IHC design guide
Design Immunohistochemistry for ARHGEF2
Plan chromogenic IHC for ARHGEF2 in paraffin sections using its variable cytoplasmic tissue staining as a reference (HPA tissue IHC). High staining in bone marrow hematopoietic cells and germinal center cells offers positive-control options (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Variable cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining of varying intensity across tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02572-3) | |
| Positive control | Bone marrow+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Bone marrow peroxidase may mimic DAB staining (HPA tissue IHC; standard IHC practice) | |
| Regulation | Expression regulation not established (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended ARHGEF2 IHC & IF Protocols
The catalog antibody protocol is paired with one published ARHGEF2 tissue IHC protocol (PMC9637107 methods).
| Sample | Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A02572-3) |
| Fixation | Image fixative and duration unreported (datasheet A02572-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02572-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02572-3) |
| Primary antibody | Rabbit anti-ARHGEF2, 2-5 μg/ml (datasheet A02572-3) |
| Primary incubation | Overnight at 4 °C (datasheet A02572-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02572-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF2-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression of varying intensities in several different tissue types. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval (datasheet A02572-3); the published protocol used Tris-EDTA pH 9.0 (PMC9637107 methods).
Section 2
What Is the Expected ARHGEF2 Staining Pattern?
ARHGEF2 is a cytoplasmic protein associated with the cytoskeleton, junctions and other intracellular structures; it has no transmembrane segment (UniProt Q92974). In paraffin sections, expect cytoplasmic staining in selected cell populations, especially bone marrow hematopoietic cells and lymph node or tonsil germinal center cells (HPA: High). HPA rates the tissue IHC profile Approved, with medium agreement between staining and RNA data and external verification pending (HPA).
| Clear cytoplasmic staining in bone marrow hematopoietic cells or lymph node and tonsil germinal center cells, with adjacent structures still readable. | This fits the reported High staining in those populations (HPA) and the intracellular localization of ARHGEF2 (UniProt Q92974). Intensity can vary among tissues (HPA); score the named cell population rather than the whole section. |
| A sharply nuclear, exclusively extracellular, or uniform cell-surface signal dominates the section. | Those compartments do not match the reported cytoplasmic tissue profile (HPA) or the protein's intracellular locations and lack of a transmembrane segment (UniProt Q92974). Check morphology and controls before attributing the signal to ARHGEF2. |
| Strong staining appears in adipocytes, esophageal squamous epithelial cells, or heart cardiomyocytes. | These specific cell populations are reported as Not detected (HPA). Review tissue identification and control staining; cross-reactivity or endogenous detection activity is possible (general IHC practice). A negative HPA observation is not proof of absolute protein absence. |
| Diffuse color covers cells, stroma, and empty spaces, obscuring intracellular boundaries. | This cannot be scored as the reported cytoplasmic cell staining (HPA). Background from detection reagents, inadequate blocking, or excessive antibody concentration is possible (general IHC practice); compare a matched control section. |
| No staining is visible in an adequately sampled bone marrow hematopoietic population or lymph node germinal center. | These are reported High populations (HPA), so an entirely blank result raises an assay-performance question. Check section identity, tissue preservation, retrieval, antibody exposure, and detection controls (general IHC practice) before interpreting the specimen as negative. |
💡Expected ARHGEF2 appearanceA convincing positive is predominantly cytoplasmic staining in identifiable hematopoietic or germinal center cells, potentially High in the HPA examples; dominant nuclear color or strong signal in an HPA Not detected cell population warrants control review (HPA; UniProt Q92974).
| Cell population and tissue context | HPA reports High staining in bone marrow hematopoietic cells, lymph node and tonsil germinal center cells, and late spermatids; several other populations are Medium, Low, or Not detected (HPA). Compare like cell populations when selecting controls or scoring. |
| Intracellular distribution | UniProt places ARHGEF2 in cytoplasm, cytoskeleton, tight junctions, Golgi, spindle-associated structures, ruffles, and cytoplasmic vesicles (UniProt Q92974). The HPA tissue profile summarizes variable cytoplasmic staining (HPA); routine chromogenic sections need not resolve every listed subcellular site. |
| Antibody validation and protein forms | The listed antibody HPA043437 is IHC Approved, while HPA describes medium staining–RNA agreement and pending external verification (HPA). UniProt lists 3 isoforms and a chain spanning residues 1–986 (UniProt Q92974); the payload gives no epitope, so isoform coverage cannot be inferred. |
| IF/ICC question: what localization should be expected? | Intracellular localization is biologically plausible from UniProt Q92974, but HPA provides no main ICC-IF location or cell-line images for this record (HPA subcellular). Use the separate IF/ICC guide for assay design; this IHC evidence does not establish an IF staining pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| The presumed positive control has no chromogenic signal. | The sampled section may lack the relevant cells, or a preparation or detection step may have failed (general IHC practice); HPA's High label applies to named cell populations, not every area of a tissue (HPA). | Confirm hematopoietic cells or germinal centers are present, then inspect reagent and detection controls and review the laboratory's retrieval conditions (general IHC practice). Do not assume a target-specific retrieval requirement from HPA. |
| Staining is widespread across tissue types but lacks a clear cytoplasmic pattern. | Diffuse background or nonspecific binding may be obscuring interpretable staining (general IHC practice). HPA describes cytoplasmic expression of varying intensity across tissues (HPA), which does not justify uniform color over all structures. | Compare a matched control and tissue morphology; review blocking, washing, antibody concentration, and detection exposure using the validated assay workflow (general IHC practice). Reassess the named cell populations after background is controlled. |
| Strong color appears where HPA reports Not detected staining. | Cell-type misidentification, antibody cross-reactivity, or endogenous detection activity are possibilities (general IHC practice). HPA reports Not detected adipocytes, esophageal squamous epithelial cells, and cardiomyocytes (HPA). | Verify the cell type on a counterstained section and compare reagent controls (general IHC practice). Treat the HPA entry as an observed reference pattern, with its medium agreement and pending external verification (HPA). |
| Signal seems confined to nuclei or extracellular material. | The pattern conflicts with the HPA cytoplasmic profile and UniProt intracellular localization (HPA; UniProt Q92974). Morphologic overlap, precipitate, or nonspecific signal could account for it (general IHC practice). | Check focus and cellular boundaries, inspect a matched control, and repeat scoring in a named HPA High population (general IHC practice; HPA). Do not call the unexpected compartment ARHGEF2 solely from color. |
| Two positive tissues show different staining strengths. | HPA explicitly reports variable cytoplasmic intensity: bone marrow hematopoietic cells are High, while breast glandular cells are Medium (HPA). Tissue-wide averages can also conceal differences among cell types (general IHC practice). | Score the specified cell population in each tissue and compare it with its own HPA reference level (HPA). Keep section quality and detection conditions comparable when interpreting an intensity difference (general IHC practice). |
| A result is being used to claim a specific isoform or an IF/ICC pattern. | UniProt lists three isoforms, but the supplied record does not map the antibody epitope to them (UniProt Q92974; HPA antibodies). HPA supplies no ICC-IF main location or images for this record (HPA subcellular). | Report the result as IHC staining with the catalog antibody and describe only the observed compartment and cell type (HPA; general IHC practice). Leave isoform identity and an IF/ICC pattern unresolved without separate evidence. |
Experiment evidence
IHC & IF images showing ARHGEF2 staining
A02572-3 · IHCIHC analysis of GEF-H1/ARHGEF2 using anti-GEF-H1/ARHGEF2 antibody (A02572-3). GEF-H1/ARHGEF2 was detected in a paraffin-embedded section of
A02572-3 · IHCIHC analysis of GEF-H1/ARHGEF2 using anti-GEF-H1/ARHGEF2 antibody (A02572-3). GEF-H1/ARHGEF2 was detected in a paraffin-embedded section of
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/cerebral+cortex#imid_20123245
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/colon#imid_20123171
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/liver#imid_20123180
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/kidney#imid_20123173
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF2 IHC & IF
🧪Run bone marrow first; its hematopoietic cells should stain (HPA: High in bone marrow hematopoietic cells). Use adipose tissue adipocytes as the negative comparator (HPA: Not detected in adipose tissue adipocytes); on the marrow slide, treat unstained cells outside the hematopoietic compartment as candidate internal negatives only after confirming their identity.
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for ARHGEF2; derive a cell-line control from the positive tissue's cell type (Hematopoietic cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s rabbit host and clonality (caption: rabbit primary; standard IHC practice); confirm specificity with ARHGEF2 knockout material if available (standard IHC practice). For bone marrow chromogenic IHC, quench endogenous peroxidase and check the no-primary slide for residual signal; block endogenous biotin if using biotin-based detection (caption: peroxidase/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A02572-3 paraffin-section caption does not state a fixative (caption: fixative not stated). Heat-mediated EDTA retrieval at pH 8.0 is a documented starting condition, but its necessity has not been established (caption: EDTA retrieval, pH 8.0). The supplied evidence does not establish whether frozen sections or IF/ICC are easier; endogenous peroxidase in bone marrow is a potential DAB artefact to assess with the no-primary control (standard IHC practice).
HPA tissue IHC evidence for ARHGEF2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | High | Protein (IHC) | HPA → |
| Testis | Elongated or late spermatids | High | Protein (IHC) | HPA → |
| Tonsil | Germinal center cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Basal cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF2 IHC Tips
Troubleshoot ARHGEF2 staining in paraffin sections by checking retrieval, cell type, cytoplasmic localisation and controls before scoring signal.
How should I adjust retrieval when ARHGEF2 staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A02572-3). The catalog antibody produced a chromogenic signal after this retrieval in a paraffin-embedded human colon cancer section, but the caption gives no heating duration (datasheet A02572-3). On adjacent sections, compare a short and longer heating interval while holding antibody concentration, detection and development constant; excessive heating can damage morphology (standard IHC practice). If signal remains weak, assess section age and antibody incubation before testing another retrieval buffer as a documented fallback, with a positive control alongside each condition (standard IHC practice).
Could fixation explain inconsistent ARHGEF2 staining between blocks?
Target-specific fixation sensitivity for ARHGEF2 is unknown: the catalog image describes a paraffin-embedded section but does not state its fixative (datasheet A02572-3). Record each block's fixative and fixation duration, then compare sections processed with the same EDTA pH 8.0 retrieval and chromogenic detection (datasheet A02572-3; standard IHC practice). Include an internal positive population or a separately processed positive control so weak staining can be judged against tissue preservation and processing differences (standard IHC practice). Do not infer fixation tolerance from cytoplasmic localisation, phosphorylation sites or the tissue expression profile; none supplies a fixation comparison (UniProt Q92974; HPA tissue IHC).
Which staining pattern is plausible for ARHGEF2 in tissue sections?
Expect predominantly cytoplasmic signal in tissue IHC, with intensity varying by tissue and cell population (HPA tissue IHC). ARHGEF2 also associates with cytoskeleton, tight junctions, Golgi, spindle, ruffles and cytoplasmic vesicles, and has no transmembrane segment (UniProt Q92974 subcellular; UniProt Q92974 topology). Examine whether apparent junctional or punctate staining sits within the expected cells and persists across well-preserved areas; chromogenic sections may not resolve these structures individually (standard IHC practice). A purely nuclear or continuous cell-surface pattern warrants review of morphology, antibody specificity and detection controls before assignment to ARHGEF2 (UniProt Q92974 subcellular; standard IHC practice).
Can epitope position change how I interpret ARHGEF2 staining?
ARHGEF2 has 3 annotated isoforms, but the supplied catalog caption does not identify the antibody's epitope or establish which isoforms it detects (UniProt Q92974 isoforms; datasheet A02572-3). Map the immunogen against each isoform before interpreting differences between tissue populations as isoform differences (standard antibody validation practice). The protein contains a DH domain at residues 235–432, a PH domain at 472–571, and multiple annotated modified residues, including N-terminal phosphoserines (UniProt Q92974 domains; UniProt Q92974 modified residues). These annotations guide epitope review but do not establish that a modification or domain changes this antibody's staining; compare orthogonal evidence when that distinction matters (standard antibody validation practice).
How can I check an IHC pattern with multiplex IF?
Treat multiplex IF as a separate validation experiment because the supplied subcellular record lists no cell lines with ICC/IF images (HPA subcellular). Pair ARHGEF2 with a validated marker for the population under study, such as germinal center cells in lymphoid tissue, and check whether signal occupies those cells (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before assigning a weak signal to ARHGEF2 (standard IF practice). Because ARHGEF2 is intracellular and lacks a transmembrane segment, test gentle permeabilisation if the mapped epitope is intracellular, while checking that morphology and the companion marker remain intact (UniProt Q92974 subcellular; UniProt Q92974 topology; standard IF practice).
What should I change when DAB appears throughout the section?
The catalog example used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and peroxidase detection with DAB (datasheet A02572-3). If diffuse colour obscures cells, inspect a no-primary control and a matched section with an endogenous peroxidase block to separate detection background from antibody-dependent signal (standard IHC practice). Titrate primary concentration and shorten DAB development one variable at a time, while retaining a positive tissue control (standard IHC practice). Recheck washing, section edges and pigment before calling a diffuse deposit ARHGEF2, since the expected tissue profile is cytoplasmic staining of varying intensity (HPA tissue IHC; standard IHC practice).
How should I score ARHGEF2 across differently cellular regions? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, then record cytoplasmic intensity and the percentage of positive cells within that population (HPA tissue IHC; standard IHC scoring practice). An H-score can combine percentages at intensity grades 0–3; report its scoring rules and use identical thresholds across slides (standard IHC scoring practice). For spatial analyses, report positive-cell density per mm² of viable tissue and normalise to the number of eligible cells or eligible tissue area, as appropriate (standard IHC scoring practice). Keep necrotic, folded and edge regions out of the denominator, and report cell-type composition because ARHGEF2 intensity varies among tissues and populations (HPA tissue IHC; standard IHC scoring practice).
How do I distinguish genuine ARHGEF2 signal from artefact?
Judge a candidate positive by its cytoplasmic placement and by whether the stained cells match the annotated tissue population; HPA reports high signal in germinal center cells and bone marrow hematopoietic cells (HPA tissue IHC). Compare it with a no-primary control and with tissue regions processed on the same slide, since endogenous peroxidase can produce DAB signal (standard IHC practice). Exclude edge-darkening, necrosis and trapped chromogen before scoring, and scrutinise exclusively nuclear or uninterrupted surface staining against ARHGEF2's annotated intracellular locations (UniProt Q92974 subcellular; standard IHC practice). HPA rates the tissue staining Approved with medium RNA concordance and pending external verification, so a disputed pattern merits orthogonal confirmation (HPA tissue IHC).
Boster reagents
Best ARHGEF2 / Rho guanine nucleotide exchange factor 2 IHC Antibodies
ARHGEF2 tissue IHC has a human paraffin-section image (A02572-3 image caption); IF/ICC is listed for human, mouse and rat, with no IF image supplied (M02572-1 catalog).
Real IHC data
Anti-GEF-H1/ARHGEF2 Antibody ®
Cat # A02572-3
A02572-3 has IHC images from paraffin-embedded human colon and ovarian cancer sections (A02572-3 image captions). M02572-1 lists ICC/IF for human, mouse and rat, but supplies no IF image (M02572-1 catalog).
Which to pick: Choose A02572-3 for tissue IHC: its own captions show paraffin sections, and the fixative is unreported (A02572-3 image captions). Choose monoclonal M02572-1 for IF/ICC because that application is listed for it; it has no listed IHC validation (M02572-1 catalog). Both list human, mouse and rat reactivity, but the supplied IHC images show human tissue only (A02572-3 catalog and image captions; M02572-1 catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q92974 (ARHG2_HUMAN, Rho guanine nucleotide exchange factor 2).
- Human Protein Atlas. ARHGEF2 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGEF2 subcellular location (ICC-IF): Highest expression in THP-1: 180.9 nTPM.
- Human Protein Atlas. ARHGEF2 antibody validation summary (1 antibodies).
- Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer. Cell death & disease 2022 — PMC9637107.
- CCDC88B interacts with RASAL3 and ARHGEF2 and regulates dendritic cell function in neuroinflammation and colitis. Communications biology 2024 — PMC10781698.
- PubMed PMID:9857026 — UniProt-cited evidence.
- PubMed PMID:11912491 — UniProt-cited evidence.
- PubMed PMID:9734811 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF2 (Rho guanine nucleotide exchange factor 2). Expected localisation Variable cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02572-3). Validated IHC antibody: A02572-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A02572-3); 2. Fixation: Image fixative and duration unreported (datasheet A02572-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02572-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02572-3); 8. Primary antibody: Rabbit anti-ARHGEF2, 2-5 μg/ml (datasheet A02572-3); 9. Primary incubation: Overnight at 4 °C (datasheet A02572-3). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Bone marrow peroxidase may mimic DAB staining (HPA tissue IHC; standard IHC practice); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt); Regulation: Expression regulation not established (UniProt). Evidence: UniProt Q92974, HPA tissue IHC · Approved, HPA cell-line RNA · Highest expression in THP-1: 180.9 nTPM, Datasheet A02572-3, PMC9637107. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF2/immunohistochemistry-ihc-guide.